This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that…
Reuters Health Information